Search research articles
Contact Us
Filters
Showing results (151-160 of 188) with videos related to
Page
of 19
Sort By:
Leukemia
|
December 10, 2014
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib
D Guinn, A S Ruppert, K Maddocks, et al.
Leukemia
|
July 14, 2012
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
A J Johnson, Y-Y Yeh, L L Smith, et al.
Leukemia
|
October 22, 2005
The evolving role of alemtuzumab in management of patients with CLL
S Faderl, S Coutré, J C Byrd, et al.
Leukemia
|
February 1, 2012
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
J A Woyach, G Lozanski, A S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
J C Byrd, R K Dodge, A Carroll, et al.
Bone Marrow Transplantation
|
February 16, 2005
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
S S Farag, B J Bolwell, P J Elder, et al.
Leukemia
|
April 30, 2004
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells
D M Lucas, M E Davis, M R Parthun, et al.
Leukemia
|
July 21, 2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2
A-K Eisfeld, J Kohlschmidt, K Mrózek, et al.
Cancer Research
|
September 29, 1998
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
C D Bloomfield, D Lawrence, J C Byrd, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 30, 2000
Enhanced pneumocystis carinii activity of new primaquine analogues
T E Goodwin, C J Boylan, W L Current, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 188) with videos related to
Sort By:
Page
of 19
Leukemia
|
December 10, 2014
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib
D Guinn, A S Ruppert, K Maddocks, et al.
Leukemia
|
July 14, 2012
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
A J Johnson, Y-Y Yeh, L L Smith, et al.
Leukemia
|
October 22, 2005
The evolving role of alemtuzumab in management of patients with CLL
S Faderl, S Coutré, J C Byrd, et al.
Leukemia
|
February 1, 2012
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
J A Woyach, G Lozanski, A S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
J C Byrd, R K Dodge, A Carroll, et al.
Bone Marrow Transplantation
|
February 16, 2005
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
S S Farag, B J Bolwell, P J Elder, et al.
Leukemia
|
April 30, 2004
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells
D M Lucas, M E Davis, M R Parthun, et al.
Leukemia
|
July 21, 2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2
A-K Eisfeld, J Kohlschmidt, K Mrózek, et al.
Cancer Research
|
September 29, 1998
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
C D Bloomfield, D Lawrence, J C Byrd, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 30, 2000
Enhanced pneumocystis carinii activity of new primaquine analogues
T E Goodwin, C J Boylan, W L Current, et al.
Page
of 19